Asset profile
QiShenYiQi
Botanical
Evidence outlook · lead readout
NCT04944706 · Chronic Heart Failure With Preserved Ejection Fraction
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04944706: The study was randomized and quadruple-blinded, with two QiShenYiQi dose groups and a placebo group, and enrolled 225 participants. Its primary clinical functional endpoint was 6-minute walking distance, but whether that endpoint was met cannot be determined because results are not posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.